目的:建立稳定转染人宫颈癌癌基因(human cervical cancer oncogene,HCCR)siRNA真核表达质粒的人胰腺癌PANC1细胞株,探讨siRNA干扰HCCR的表达后对人胰腺癌PANC1细胞增殖、凋亡和侵袭的影响。方法:通过脂质体转染法将含HCCRsiRNA的真核...目的:建立稳定转染人宫颈癌癌基因(human cervical cancer oncogene,HCCR)siRNA真核表达质粒的人胰腺癌PANC1细胞株,探讨siRNA干扰HCCR的表达后对人胰腺癌PANC1细胞增殖、凋亡和侵袭的影响。方法:通过脂质体转染法将含HCCRsiRNA的真核表达质粒pGCsi-HCCR稳定转染至人胰腺癌细胞株PANC1,抗生素G418筛选获得稳转细胞株;Western blot检测PANC1细胞中HCCR的表达,同时检测肿瘤相关基因p53蛋白表达的变化;流式细胞仪检测PANC1细胞的细胞周期和凋亡率变化;MTT比色法检测siRNA干扰后对PANC1细胞增殖能力的影响;Transwell侵袭实验观察siRNA干扰后对PANC1细胞侵袭能力的影响。结果:Western blot证实siRNA稳转组的PANC1细胞株和空载体稳转组比较HCCR蛋白表达水平下调,稳转细胞株建立成功。siRNA稳转组p53蛋白表达下降。siRNA稳转组的S期细胞数目减少而G0/G1期细胞数目增加,细胞凋亡增加。MTT结果显示siRNA稳转组1和稳转组2细胞吸光度分别为空载体组细胞的0.65倍和0.68倍,细胞增殖能力下降。Transwell侵袭实验显示siRNA稳转组细胞和空载体组细胞穿膜数分别为24.4±9.9和49.1±15.4(P<0.01),稳转组细胞侵袭能力下降。结论:siRNA干扰HCCR的表达后能抑制胰腺癌PANC1细胞增殖和侵袭,促进其凋亡。展开更多
目的:通过生物信息学分析以及细胞生物学实验研究角蛋白6A(KRT6A)对胰腺导管腺癌(PDAC)诊断、预后判断、免疫微环境以及PDAC细胞PANC1增殖、凋亡等生物学行为的影响。方法:通过GEPIA平台整合TCGA(The Cancer Genome Atlas)数据库与GTEx(...目的:通过生物信息学分析以及细胞生物学实验研究角蛋白6A(KRT6A)对胰腺导管腺癌(PDAC)诊断、预后判断、免疫微环境以及PDAC细胞PANC1增殖、凋亡等生物学行为的影响。方法:通过GEPIA平台整合TCGA(The Cancer Genome Atlas)数据库与GTEx(Genotype-Tissue)数据库中的数据,分析KTRT6A在PDAC组织中的表达情况,并通过CIBERSORT工具分析KRT6A表达与PDAC组织中免疫细胞浸润的关系,然后通过GSEA方法研究与KRT6A基因表达相关的肿瘤信号通路。选取长海医院病理科保存的60例PDAC组织与癌旁组织标本进行免疫组化分析,验证KRT6A在肿瘤组织中表达情况;通过干扰RNA敲减PANC1细胞中KRT6A的表达,采用CCK-8实验以及流式细胞术检测敲减KRT6A对细胞的增殖、凋亡的影响。结果:利用TCGA与GTEx数据库数据分析发现,KRT6A在人PDAC组织中呈高表达,且与患者较差的生存期存在关联(P=0.015)。利用CIBERSORT软件以及GSEA分析发现,KRT6A高表达的PDAC组织中M2型巨噬细胞浸润性升高(P=0.034),且与Wnt通路(NES:1.7359272,P<0.05)、磷酸戊糖途径(PPP)(NES:1.5613053,P<0.05)等信号通路上调有关联(P<0.05或P<0.01);免疫组化结果进一步验证了KRT6A在PDAC组织中呈高表达(P<0.001)。增殖和凋亡实验发现,干扰KRT6A能够显著抑制PANC1细胞的增殖(P<0.05)以及凋亡(P<0.001)。结论:KRT6A在人PDAC组织中呈高表达,敲减其表达能够抑制PANC1细胞的增殖和凋亡,具有作为PDAC诊断与预后判断新靶标的潜力。展开更多
Enzymes 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 and -4 (PFKFB-3 and PFKFB-4) play a significant role in the regulation of glycolysis in cancer cells as well as its proliferation and survival. The expres...Enzymes 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 and -4 (PFKFB-3 and PFKFB-4) play a significant role in the regulation of glycolysis in cancer cells as well as its proliferation and survival. The expression of these mRNAs is increased in malignant tumors and strongly induced in different cancer cell lines by hypoxia inducible factor (HIF) through active HIF binding sites in promoter region of PFKFB-4 and PFKFB-3 genes. Moreover, the expression and hypoxia responsibility of PFKFB-4 and PFKFB-3 was also shown for pancreatic (Panc1, PSN-1, and MIA PaCa-2) as well as gastric (MKN45 and NUGC3) cancer cells. At the same time, their basal expression level and hypoxia responsiveness vary in the different cells studied: the highest level of PFKFB-4 protein expression was found in NUGC3 gastric cancer cell line and lowest in Panc1 cells, with a stronger response to hypoxia in the pancreatic cancer cell line. Overexpression of different PFKFB in pancreatic and gastric cancer cells under hypoxic condition is correlated with enhanced expression of vascular endothelial growth factor (VEGF) and Glut1 mRNA as well as with increased level of HIF-1α protein. Increased expression of different PFKFB genes was also demonstrated in gastric, lung, breast, and colon cancers as compared to corresponding non-malignant tissue counterparts from the same patients, being more robust in the breast and lung tumors. Moreover, induction of PFKFB-4 mRNA expression in the breast and lung cancers is stronger than PFKFB-3 mRNA. The levels of both PFKFB-4 and PFKFB-3 proteins in non-malignant gastric and colon tissues were more pronounced than in the non-malignant breast and lung tissues. It is interesting to note that Panc1 and PSN-1 cells transfected with dominant/negative PFKFB-3 (dnPFKFB-3) showed a lower level of endogenous PFKFB-3, PFKFB-4, and VEGF mRNA expressions as well as a decreased proliferation rate of these cells. Moreover, a similar effect had dnPFKFB-4. In conclusion, there is strong evidence that PFKFB-4 and PFKFB-3 isoenzymes are induced under hypoxia in pancreatic and other cancer cell lines, are overexpressed in gastric, colon, lung, and breast malignant tumors and undergo changes in their metabolism that contribute to the proliferation and survival of cancer cells. Thus, targeting these PFKFB may therefore present new therapeutic opportunities.展开更多
文摘目的:通过生物信息学分析以及细胞生物学实验研究角蛋白6A(KRT6A)对胰腺导管腺癌(PDAC)诊断、预后判断、免疫微环境以及PDAC细胞PANC1增殖、凋亡等生物学行为的影响。方法:通过GEPIA平台整合TCGA(The Cancer Genome Atlas)数据库与GTEx(Genotype-Tissue)数据库中的数据,分析KTRT6A在PDAC组织中的表达情况,并通过CIBERSORT工具分析KRT6A表达与PDAC组织中免疫细胞浸润的关系,然后通过GSEA方法研究与KRT6A基因表达相关的肿瘤信号通路。选取长海医院病理科保存的60例PDAC组织与癌旁组织标本进行免疫组化分析,验证KRT6A在肿瘤组织中表达情况;通过干扰RNA敲减PANC1细胞中KRT6A的表达,采用CCK-8实验以及流式细胞术检测敲减KRT6A对细胞的增殖、凋亡的影响。结果:利用TCGA与GTEx数据库数据分析发现,KRT6A在人PDAC组织中呈高表达,且与患者较差的生存期存在关联(P=0.015)。利用CIBERSORT软件以及GSEA分析发现,KRT6A高表达的PDAC组织中M2型巨噬细胞浸润性升高(P=0.034),且与Wnt通路(NES:1.7359272,P<0.05)、磷酸戊糖途径(PPP)(NES:1.5613053,P<0.05)等信号通路上调有关联(P<0.05或P<0.01);免疫组化结果进一步验证了KRT6A在PDAC组织中呈高表达(P<0.001)。增殖和凋亡实验发现,干扰KRT6A能够显著抑制PANC1细胞的增殖(P<0.05)以及凋亡(P<0.001)。结论:KRT6A在人PDAC组织中呈高表达,敲减其表达能够抑制PANC1细胞的增殖和凋亡,具有作为PDAC诊断与预后判断新靶标的潜力。
文摘Enzymes 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 and -4 (PFKFB-3 and PFKFB-4) play a significant role in the regulation of glycolysis in cancer cells as well as its proliferation and survival. The expression of these mRNAs is increased in malignant tumors and strongly induced in different cancer cell lines by hypoxia inducible factor (HIF) through active HIF binding sites in promoter region of PFKFB-4 and PFKFB-3 genes. Moreover, the expression and hypoxia responsibility of PFKFB-4 and PFKFB-3 was also shown for pancreatic (Panc1, PSN-1, and MIA PaCa-2) as well as gastric (MKN45 and NUGC3) cancer cells. At the same time, their basal expression level and hypoxia responsiveness vary in the different cells studied: the highest level of PFKFB-4 protein expression was found in NUGC3 gastric cancer cell line and lowest in Panc1 cells, with a stronger response to hypoxia in the pancreatic cancer cell line. Overexpression of different PFKFB in pancreatic and gastric cancer cells under hypoxic condition is correlated with enhanced expression of vascular endothelial growth factor (VEGF) and Glut1 mRNA as well as with increased level of HIF-1α protein. Increased expression of different PFKFB genes was also demonstrated in gastric, lung, breast, and colon cancers as compared to corresponding non-malignant tissue counterparts from the same patients, being more robust in the breast and lung tumors. Moreover, induction of PFKFB-4 mRNA expression in the breast and lung cancers is stronger than PFKFB-3 mRNA. The levels of both PFKFB-4 and PFKFB-3 proteins in non-malignant gastric and colon tissues were more pronounced than in the non-malignant breast and lung tissues. It is interesting to note that Panc1 and PSN-1 cells transfected with dominant/negative PFKFB-3 (dnPFKFB-3) showed a lower level of endogenous PFKFB-3, PFKFB-4, and VEGF mRNA expressions as well as a decreased proliferation rate of these cells. Moreover, a similar effect had dnPFKFB-4. In conclusion, there is strong evidence that PFKFB-4 and PFKFB-3 isoenzymes are induced under hypoxia in pancreatic and other cancer cell lines, are overexpressed in gastric, colon, lung, and breast malignant tumors and undergo changes in their metabolism that contribute to the proliferation and survival of cancer cells. Thus, targeting these PFKFB may therefore present new therapeutic opportunities.
